anxiolytic effects – Page 2

Psychotomimetic compensation versus sensitization

mycolabadmin

This paper proposes a new way to understand why drugs that can cause psychosis-like effects (such as psilocybin, LSD, and ketamine) can also help treat depression and anxiety. The authors suggest that these drugs trigger compensatory responses in the brain that temporarily help us cope with stress, similar to how a runner’s high feels good during exercise. However, if someone uses these drugs repeatedly or experiences chronic stress, they may become sensitized and more vulnerable to developing actual psychotic symptoms over time.

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

mycolabadmin

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

mycolabadmin

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

mycolabadmin

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

mycolabadmin

This comprehensive review explores how psychedelic drugs like psilocybin mushrooms, DMT, and LSD may offer new hope for treating depression, anxiety, and PTSD, especially for patients who don’t respond to conventional antidepressants. Historically used in spiritual ceremonies for thousands of years, these compounds are now being scientifically studied and show promise with fewer side effects than many traditional psychiatric medications. The authors emphasize that while results are encouraging, more research and regulatory approval are needed before these treatments become widely available in mainstream medicine.

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice

mycolabadmin

This study examined how psilocybin works to reduce anxiety in mice by investigating the role of stress hormones, particularly corticosterone. Researchers found that psilocybin causes a temporary spike in corticosterone levels that is essential for its anxiety-reducing effects hours after administration. Interestingly, other interventions that increase corticosterone levels also produced similar anxiety-reducing effects, suggesting the stress hormone response itself drives the therapeutic benefit rather than psilocybin’s psychedelic properties alone. These findings suggest that measuring cortisol levels in human patients receiving psilocybin therapy could help explain and optimize therapeutic outcomes.

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

mycolabadmin

This review examines the safety of psilocybin therapy for treating anorexia nervosa, a serious eating disorder with limited treatment options. The authors analyze how psilocybin’s common side effects (like increased heart rate, nausea, and dizziness) interact with medical complications already present in people with anorexia. Based on early clinical trials, they conclude that psilocybin can be safely used in this population with proper medical screening and monitoring protocols tailored to their specific vulnerabilities.

Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond

mycolabadmin

Researchers created new chemical versions of psilocybin (the active compound in magic mushrooms) that cannot be broken down by the body’s natural enzymes in the same way. They tested these new compounds to see if they could help with depression and anxiety by targeting specific brain receptors. The best compound worked well on the intended brain receptors but importantly showed less activity on a heart-related receptor, potentially making it safer than natural psilocybin.

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review

mycolabadmin

Psilocybin, a naturally occurring compound found in certain mushroom species, shows significant promise as a treatment for depression. Clinical studies reviewed in this research found that psilocybin-assisted therapy reduced depressive symptoms in every patient studied, with improvements lasting months after treatment. Unlike traditional antidepressants, psilocybin caused only mild temporary side effects and worked faster, suggesting it could become an important alternative treatment for depression.

therapeutic action: anxiolytic effects